Directorate change

About this update from Reckitt Benckiser Group Plc

RECKITT BENCKISER GROUP PLC DIRECTORATE CHANGE   Reckitt announces the appointment of Harry Kirsch and Deepak Nath as Non-Executive Directors and the resignation of Margherita Della Valle and Mahesh Madhavan   Reckitt Benckiser Group plc (the " Company " or " Reckitt ") today announces the appointment of Harry Kirsch, current CFO of Novartis Pharma AG and Deepak Nath, current CEO of Smith+Nephew plc, to the Board as Non-Executive Directors, effective 1 April 2026.   Harry is currently CFO of Novartis, having joined in 2003 and held a number of senior finance roles before being promoted to his current role in 2013. He is retiring in mid-March. Prior to Novartis, Harry spent 12 years at Procter & Gamble in various finance roles. He was a Non-Executive Director at GlaxoSmithKline Consumer Healthcare Holdings Ltd between 2015-2018.   Harry currently serves as a Non-Executive Director of the Novartis Venture Fund.   Harry will join the Audit Committee from May 2026.   Deepak Nath is currently CEO of Smith+Nephew plc having joined in 2022. Prior to that Deepak held senior roles at Siemens Healthineers, Abbott Laboratories Inc, Amgen Inc and McKinsey and Co Inc.   Deepak is currently a director of MDIC and AdvaMed.   Margherita Della Valle and Mahesh Madhavan, Non-Executive Director's, have informed the Company of their intention to retire from the Board with effect from 1 April 2026.    Commenting on the Board changes, Sir Jeremy Darroch, Chair of the Board said:   "I would like to thank Margherita and Mahesh for their valued contributions to the Board and respective Committee's. We are delighted that Harry and Deepak will be joining the Reckitt Board, bringing many years of executive leadership experience of large global businesses and w e welcome the value and expertise both will bring to the Board."   The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointments.     Contact Details:   Catheryn O'Rourke                                                         +44 (0) 1753 217 800 General Counsel & Company Secretary   Nick Ashworth                                                                +44 (0) 7408 812350 Investor Relations     About Reckitt:   Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.   Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.   Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.   We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society.  Find out more, or get in touch with us at  www.reckitt.com   * Reckitt is the trading name of the Reckitt Benckiser group of companies   Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108  

View stock analysis, news, and events for Reckitt Benckiser Group Plc